We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals’ Orkambi has been approved as the first drug intended to treat cystic fibrosis in patients who have two copies of a specific mutation, the FDA announced Friday. Read More
A federal judge has ordered Apotex to pay AstraZeneca $98.5 million for infringing on patents to the latter’s heartburn drug Prilosec, following an appellate decision affirming most of a $76 million award from a 2013 ruling. Read More
Genentech, whose scleroderma treatment Actemra recently gained breakthrough therapy status from the FDA, topped the list of drugmakers making payments to physicians and teaching hospitals last year, with at least $274.2 million in general payments and $99.2 million in research payments covering more than 16,000 transactions. Read More
Celgene and Juno Therapeutics have entered into a 10-year collaboration leveraging their T cell strategies to develop treatments for patients with cancer and autoimmune diseases. Read More
Roche announced positive results from two Phase 3 studies pitting its investigational multiple sclerosis drug ocrelizumab against the standard-of-care in patients with relapsing MS, the most common form of the disease. Read More
The UK’s healthcare watchdog says it needs more evidence before it can determine if off-label use of Alexion’s Soliris is effective in preventing the recurrence of a rare kidney disease in patients who have undergone transplants. Read More